Expression of intestinal drug transporter proteins and metabolic enzymes in neonatal and pediatric patients.

Drug transporter proteins Gastrointestinal ontogeny Metabolic enzymes Neonates Pediatric patients

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
01 Mar 2024
Historique:
received: 20 01 2024
revised: 28 02 2024
accepted: 28 02 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 3 3 2024
Statut: aheadofprint

Résumé

The development of pediatric oral drugs is hampered by a lack of predictive simulation tools. These tools, in turn, require data on the physiological variables that influence oral drug absorption, including the expression of drug transporter proteins (DTPs) and drug-metabolizing enzymes (DMEs) in the intestinal tract. The expression of hepatic DTPs and DMEs shows age-related changes, but there are few data on protein levels in the intestine of children. In this study, tissue was collected from different regions of the small and large intestine from neonates (i.e., surgically removed tissue) and from pediatric patients (i.e., gastroscopic duodenal biopsies). The protein expression of clinically relevant DTPs and DMEs was determined using a targeted mass spectrometry approach. The regional distribution of DTPs and DMEs was similar to adults. Most DTPs, with the exception of MRP3, MCT1, and OCT3, and all DMEs showed the highest protein expression in the proximal small intestine. Several proteins (i.e., P-gp, ASBT, CYP3A4, CYP3A5, CYP2C9, CYP2C19, and UGT1A1) showed an increase with age. Such increase appeared to be even more pronounced for DMEs. This exploratory study highlights the developmental changes in DTPs and DMEs in the intestinal tract of the pediatric population. Additional evaluation of protein function in this population would elucidate the implications of the presented changes in protein expression on absorption of orally administered drugs in neonates and pediatric patients.

Identifiants

pubmed: 38432450
pii: S0378-5173(24)00196-0
doi: 10.1016/j.ijpharm.2024.123962
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123962

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Patrick Augustijns reports financial support was provided by Research Foundation Flanders. The authors declare no conflict of interest. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Tom de Waal (T)

Drug Delivery and Disposition, KU Leuven, Leuven, Belgium.

Niklas Handin (N)

Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Joachim Brouwers (J)

Drug Delivery and Disposition, KU Leuven, Leuven, Belgium.

Marc Miserez (M)

Department of Abdominal Surgery, University Hospitals Leuven, Leuven, Belgium.

Ilse Hoffman (I)

Pediatric Gastroenterology, Hepatology and Nutrition, University Hospitals Leuven, Leuven, Belgium.

Maissa Rayyan (M)

Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.

Per Artursson (P)

Department of Pharmacy, Uppsala University, Uppsala, Sweden.

Patrick Augustijns (P)

Drug Delivery and Disposition, KU Leuven, Leuven, Belgium.

Classifications MeSH